Pilot SBIR trial: MBI-guided biopsy using radiotracer uptake to target tumor metabolism.

This pilot trial by Smart Breast Corp. compares supplemental molecular breast imaging (MBI) to standard digital breast tomosynthesis (DBT) for cancer detection in women with dense breasts (BIRADS C or D). Participants receive both screenings and, if indicated, are randomly assigned to either DBT-guided or MBI-guided biopsy. Today, dense-breast screening typically relies on mammography/DBT (with ultrasound or MRI in select cases); MBI isn’t routine. The study asks whether MBI can detect additional cancers and better steer biopsies than DBT, potentially improving accuracy in this harder-to-image group.